{"id":"liraglutide-standard-of-care-treatment","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Headache"},{"rate":"5","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4084119","moleculeType":"Protein","molecularWeight":"3751.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion while simultaneously inhibiting glucagon release when blood glucose is elevated. This dual action, combined with delayed gastric emptying and reduced appetite, leads to improved glycemic control. When combined with standard-of-care treatment, it provides additive benefit in managing type 2 diabetes and potentially reducing cardiovascular risk.","oneSentence":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion, suppress glucagon, and slow gastric emptying, used here in combination with standard diabetes care.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:32.848Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (in combination with standard-of-care treatment)"}]},"trialDetails":[{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT05756764","phase":"","title":"Anti-obesity Pharmacotherapy and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2023-06-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT05812183","phase":"PHASE4","title":"Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-07-09","conditions":"Dyspnea, Quality of Life","enrollment":""},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT03885297","phase":"","title":"3mg Liraglutide for Overweight or Obesity","status":"COMPLETED","sponsor":"University Hospitals Coventry and Warwickshire NHS Trust","startDate":"2019-01-18","conditions":"Overweight, Obesity, Infertility, Female","enrollment":43},{"nctId":"NCT05390307","phase":"NA","title":"Obesity Treatment to Improve Diabetes","status":"COMPLETED","sponsor":"Dasman Diabetes Institute","startDate":"2023-04-01","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT03948347","phase":"NA","title":"Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Jinan University","startDate":"2019-06-25","conditions":"Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus","enrollment":1708},{"nctId":"NCT02041234","phase":"PHASE4","title":"Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment","status":"COMPLETED","sponsor":"Khoo Teck Puat Hospital","startDate":"2014-02","conditions":"Type II Diabetes in Subjects BMI 27 to 32","enrollment":40},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT02205528","phase":"PHASE2","title":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-18","conditions":"Diabetes, Diabetes Mellitus Type 2","enrollment":108},{"nctId":"NCT01847313","phase":"PHASE3","title":"The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Karl Neff","startDate":"2013-04","conditions":"Diabetic Kidney Disease","enrollment":20},{"nctId":"NCT02423824","phase":"PHASE3","title":"Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-05","conditions":"Bipolar Disorder, Major Depressive Disorder","enrollment":21},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6125559,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Victoza"],"phase":"marketed","status":"active","brandName":"Liraglutide+standard-of-care treatment","genericName":"Liraglutide+standard-of-care treatment","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide activates GLP-1 receptors to enhance insulin secretion, suppress glucagon, and slow gastric emptying, reducing blood glucose levels. Used for Type 2 diabetes mellitus (in combination with standard-of-care treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}